Compare Agnico Eagle Mines Ltd (AEM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Crispr Therapeutics AG — how do they compare? Agnico Eagle Mines Ltd trades at $184.84 (market cap $92.01B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: Agnico Eagle Mines Ltd is far larger — about 17.6× Crispr Therapeutics AG's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AEM | CRSP | |
|---|---|---|
Market Cap | $92.01B | $5.23B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $76.78 |
52-Week Low | $130.23 | $44.34 |
Enterprise Value | $88.85B | $3.65B |
Dividend Yield | 0.99% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
